Cite

HARVARD Citation

    Slomovitz, B. et al. (2020). Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. International journal of gynecological cancer. 30 (11), pp. 1733-1737. [Online]. 
  
Back to record